Pooled Efficacy from Two Phase 3 Pivotal Trials (RELIEF AND RESILIENT) of TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, in Patients with Fibromyalgia
Pain Management Nursing · 2026-04 · 27 (2) · e244-e245
DOI: 10.1016/j.pmn.2026.01.075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Management Nursing, 2026-04. Verfasst von Errol Gould und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gould, E., Lederman, S., Engels, J., & Sullivan, G. (2026). Pooled Efficacy from Two Phase 3 Pivotal Trials (RELIEF AND RESILIENT) of TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, in Patients with Fibromyalgia. Pain Management Nursing, 27(2), e244-e245. https://doi.org/10.1016/j.pmn.2026.01.075
Vancouver
Gould E, Lederman S, Engels J, Sullivan G. Pooled Efficacy from Two Phase 3 Pivotal Trials (RELIEF AND RESILIENT) of TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, in Patients with Fibromyalgia. Pain Management Nursing. 2026;27(2):e244-e245. doi:10.1016/j.pmn.2026.01.075
BibTeX
@article{Gould2026,
author = {Gould, Errol and Lederman, Seth and Engels, Jean and Sullivan, Gregory},
title = {Pooled Efficacy from Two Phase 3 Pivotal Trials (RELIEF AND RESILIENT) of TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, in Patients with Fibromyalgia},
journal = {Pain Management Nursing},
year = {2026},
volume = {27},
number = {2},
pages = {e244--e245},
doi = {10.1016/j.pmn.2026.01.075}
}
EUVIMED